News
-
Mark Copley of Copley Scientific answers questions about upcoming changes to nebulizer testing requirements. Q: What are the new nebulizer testing requirements, and when do they come into force? A: Both the United States Pharmacopoeia… Read more . . .
-
Abstract submission deadlines for the two largest scientific meetings of OINDP specialists are approaching rapidly. The 22nd Drug Delivery to the Lungs (DDL) meeting will take place December 7-9, 2011 in Edinburgh, UK; Respiratory Drug… Read more . . .
-
Michigan-based biopharmaceutical company NanoBio has announced plans to advance its intranasal influenza vaccine into human trials after publishing results from a successful ferret study of the vaccine. The data gained from the ferret study appears… Read more . . .
-
Acknowledging that in its treatment of asthma and COPD, “we deliver health outcomes that fall some way behind those achieved by the best-performing countries, or the outcomes public health specialists and clinicians tell us are… Read more . . .
-
MedImmune has announced its submission of a supplemental Biologics License Application to the FDA for a version of its FluMist intranasal influenza vaccine that includes 4 strains of influenza virus as opposed to the usual… Read more . . .
-
Inhaled antibiotic developer Insmed has hired Andrea (“Andi”) Holtzman Drucker as its Senior Vice President, General Counsel and Corporate Secretary, which is a newly-created position reporting directly to Insmed President and CEO Timothy Whitten. Drucker… Read more . . .
-
A study by Harvard researchers published in the New England Journal of Medicine found that patients reported similar relief of symptoms from use of a placebo inhaler compared to use of an albuterol inhaler. Although… Read more . . .
-
The Allergy & Asthma Network Mothers of Asthmatics (AANMA) is currently sponsoring an Ultimate Inhaler Contest,” challenging lay people to “invent the ultimate inhaled medication device.” Read more . . .
-
University of South Florida researchers have successfully delivered an anti-inflammatory drug to the lower lungs of rats by injecting a formulation of Sertolli cells, chitosan nanoparticles, and curcumin into the rats’ tails. Over 90% of… Read more . . .
-
After a successful audit by the UK MHRA, Melbourn Scientific has been issued a manufacturing license and now has the capability to manufacture OINDPs for use in Phase 1 and 2 clinical trials, according to… Read more . . .

Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
May 30-June 2: ISAM Congress 2027, Dublin, Ireland
June 23: SMI London, London, UK


